NCT04267887View on ClinicalTrials.gov

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Antiandrogen Therapy

Given ADT per standard of care

DRUG

Apalutamide

Given PO

DRUG

Prednisone

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER